Mebendazole added to stage 4 colon cancer care
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding mebendazole (an existing anti-parasite medicine) to standard treatment can improve outcomes for people with stage 4 colon cancer. You might qualify if you have stage 4 colorectal cancer and none of the key safety concerns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal (colon or rectal) cancer that is stage 4
- You are not pregnant
- You have no known allergy to mebendazole
- You do not have agranulocytosis (a rare condition with very low infection-fighting white blood cells)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.
This trial tests whether adding a short course of antibiotics to your standard first chemotherapy for stage 4 colorectal cancer can improve treatment. The antibiotics target certain gut bacteria that might affect how well the chemo works.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests whether a combination chemotherapy (Folfiri) plus cetuximab works better for people with stage IV colorectal cancer that has specific tumor gene markers and a specific blood-gene type. It may help you shrink tumors or control the cancer if you match the study’s required lab and health criteria.
This trial tests a combination of three chemotherapy drugs plus a targeted therapy as a first treatment for advanced colorectal cancer. The goal is to see if this strong drug mix can shrink tumors better than standard approaches.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.